{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:58:00Z","timestamp":1783745880016,"version":"3.55.0"},"reference-count":95,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,11]]},"DOI":"10.18632\/oncotarget.11767","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T03:39:52Z","timestamp":1472701192000},"page":"67650-67660","source":"Crossref","is-referenced-by-count":14,"title":["Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?"],"prefix":"10.18632","volume":"7","author":[{"given":"Kai","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fandi","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Geriatric Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Geriatric Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"issue":"2","key":"1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11481-013-9484-2","article-title":"Targeting the PDGF signaling pathway in the treatment of non-malignant diseases","volume":"9","author":"Heldin","year":"2014","journal-title":"Journal of neuroimmune pharmacology"},{"key":"2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Friedman","year":"2011","journal-title":"Annual review of pathology"},{"issue":"Suppl 1","key":"3","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","article-title":"Liver fibrosis -- from bench to bedside","volume":"38","author":"Friedman","year":"2003","journal-title":"Journal of hepatology"},{"issue":"1","key":"4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/156800908783497113","article-title":"Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors","volume":"8","author":"Vassal","year":"2008","journal-title":"Current cancer drug targets"},{"issue":"12","key":"5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors","volume":"9","author":"Ghofrani","year":"2010","journal-title":"Nature reviews Drug discovery"},{"issue":"2","key":"6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep.24427","article-title":"Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis","volume":"54","author":"Shah","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2001-17554","article-title":"Cytokine receptors and signaling in hepatic stellate cells","volume":"21","author":"Marra","year":"2001","journal-title":"Seminars in liver disease"},{"issue":"Suppl 1","key":"8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1476-5926-2-S1-S3","article-title":"Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis","volume":"3","author":"Kawada","year":"2004","journal-title":"Comparative hepatology"},{"issue":"2","key":"9","first-page":"119","article-title":"[Mechanism of hepatic stellate cell migration during liver fibrosis]","volume":"88","author":"Chen","year":"2008","journal-title":"Zhonghua yi xue za zhi"},{"issue":"6","key":"10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"issue":"19","key":"11","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation","volume":"67","author":"El-Deiry","year":"2007","journal-title":"Cancer research"},{"issue":"5","key":"12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3892\/etm.2010.131","article-title":"Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media","volume":"1","author":"Yoshida","year":"2010","journal-title":"Experimental and therapeutic medicine"},{"issue":"1","key":"13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Jiang","year":"2010","journal-title":"Journal of hepatology"},{"issue":"5","key":"14","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Fukui","year":"2005","journal-title":"American journal of physiology Gastrointestinal and liver physiology"},{"issue":"8","key":"15","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Schnell","year":"2000","journal-title":"Cancer research"},{"issue":"2","key":"16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/labinvest.2008.127","article-title":"PTK787\/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling","volume":"89","author":"Fan","year":"2009","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"issue":"10","key":"17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/labinvest.2009.77","article-title":"Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787\/ZK22258","volume":"89","author":"Zhang","year":"2009","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"issue":"8","key":"18","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bbamcr.2013.02.033","article-title":"Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases","volume":"1833","author":"Mehal","year":"2013","journal-title":"Biochimica et biophysica acta"},{"issue":"2","key":"19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1472-8206.2010.00824.x","article-title":"Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression","volume":"25","author":"Ibrahim","year":"2011","journal-title":"Fundamental & clinical pharmacology"},{"key":"20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejphar.2011.08.041","article-title":"Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis","volume":"670","author":"Ibrahim","year":"2011","journal-title":"European journal of pharmacology"},{"issue":"2","key":"21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.taap.2011.02.004","article-title":"Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis","volume":"252","author":"Ibrahim","year":"2011","journal-title":"Toxicology and applied pharmacology"},{"issue":"10","key":"22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/1440-1681.12286","article-title":"Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight","volume":"41","author":"Ibrahim","year":"2014","journal-title":"Clinical and experimental pharmacology & physiology"},{"issue":"7","key":"23","first-page":"342","article-title":"Pulmonary fibrosis in a patient treated with erlotinib","volume":"29","author":"Neubauer","year":"2006","journal-title":"Onkologie"},{"issue":"4","key":"24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Gupta","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jgh.12480","article-title":"Beneficial effects of dual vascular endothelial growth factor receptor\/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats","volume":"29","author":"Liu","year":"2014","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"4","key":"26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/liv.12299","article-title":"Anti-VEGFR agents ameliorate hepatic venous dysregulation\/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat","volume":"34","author":"Lin","year":"2014","journal-title":"Liver international"},{"issue":"3","key":"27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3350\/kjhep.2007.13.3.309","article-title":"[The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis]","volume":"13","author":"Kim","year":"2007","journal-title":"The Korean journal of hepatology"},{"issue":"4","key":"28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Fernandez","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Morales-Ruiz","year":"2007","journal-title":"Hepatology"},{"key":"30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.gcb.2010.05.007","article-title":"Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology","volume":"34","author":"Rosmorduc","year":"2010","journal-title":"Gastroenterologie clinique et biologique"},{"issue":"2","key":"31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Sauerbruch","year":"2009","journal-title":"British journal of pharmacology"},{"issue":"2","key":"32","doi-asserted-by":"crossref","first-page":"e16978","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib","volume":"6","author":"Goldwasser","year":"2011","journal-title":"PloS one"},{"issue":"1","key":"33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study","volume":"35","author":"Peck-Radosavljevic","year":"2012","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"7","key":"34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jvir.2012.04.007","article-title":"Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration","volume":"23","author":"Lauenstein","year":"2012","journal-title":"Journal of vascular and interventional radiology"},{"issue":"5","key":"35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1590\/1414-431x20143962","article-title":"Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model","volume":"48","author":"Oliveira","year":"2015","journal-title":"Brazilian journal of medical and biological research"},{"issue":"4","key":"36","doi-asserted-by":"crossref","first-page":"e92273","DOI":"10.1371\/journal.pone.0092273","article-title":"Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling","volume":"9","author":"Roberts","year":"2014","journal-title":"PloS one"},{"issue":"1","key":"37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2005.06.015","article-title":"Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term","volume":"44","author":"Reichen","year":"2006","journal-title":"Journal of hepatology"},{"key":"38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Aronson","year":"2016","journal-title":"BMC medicine"},{"issue":"6","key":"39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/14622416.7.6.889","article-title":"Can pharmacogenetics help rescue drugs withdrawn from the market?","volume":"7","author":"Shah","year":"2006","journal-title":"Pharmacogenomics"},{"issue":"5","key":"40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics","volume":"57","author":"Sundaresan","year":"2006","journal-title":"Cancer chemotherapy and pharmacology"},{"issue":"7","key":"41","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Dahut","year":"2012","journal-title":"Clinical cancer research"},{"issue":"6","key":"42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/14656566.4.6.963","article-title":"Imatinib mesylate in the treatment of chronic myeloid leukaemia","volume":"4","author":"Druker","year":"2003","journal-title":"Expert opinion on pharmacotherapy"},{"issue":"7","key":"43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"6","key":"44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12231","article-title":"Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy","volume":"77","author":"Cortesi","year":"2014","journal-title":"British journal of clinical pharmacology"},{"issue":"13","key":"45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Roayaie","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"8","key":"46","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Lohse","year":"2008","journal-title":"The American journal of gastroenterology"},{"issue":"1","key":"47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Such","year":"2009","journal-title":"The American journal of gastroenterology"},{"issue":"9","key":"48","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1078-0432.CCR-13-0107","article-title":"Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial","volume":"19","author":"Burdaeva","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"25","key":"49","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial","volume":"31","author":"Neubauer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"50","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-12-3177","article-title":"Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab","volume":"19","author":"Eisenberg","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"51","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","article-title":"Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer","volume":"28","author":"Albert","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"52","article-title":"Phase II trial of sorafenib combined with doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) for patients with unresectable hepatocellular carcinoma (HCC): interim safety and efficacy analysis","author":"Reyes","year":"2010","journal-title":"Gastrointestinal cancer symposium"},{"issue":"25","key":"53","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","article-title":"Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine\/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer","volume":"30","author":"Gottfried","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"54","first-page":"29","article-title":"A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: first safety and efficacy data","author":"Kanzler","year":"2011","journal-title":"Journal of clinical oncology"},{"issue":"13","key":"55","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2007.14.8288","article-title":"Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group","volume":"26","author":"Cranmer","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Zeuzem","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"57","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Suh","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"1","key":"58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Oza","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"17","key":"59","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma","volume":"27","author":"Garbe","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejca.2012.08.005","article-title":"A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer","volume":"49","author":"Schwartzberg","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"3","key":"61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma","volume":"31","author":"Kirkwood","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"62","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma","volume":"27","author":"Bukowski","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Hutson","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Liang","year":"2009","journal-title":"Lancet Oncology"},{"key":"65","first-page":"11","article-title":"Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer","author":"Schlumberger","year":"2011","journal-title":"Bmc Cancer"},{"issue":"19","key":"66","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial","volume":"304","author":"Saltz","year":"2010","journal-title":"Jama-Journal of the American Medical Association"},{"issue":"1","key":"67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0973-6883(11)60112-6","article-title":"Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report","volume":"1","author":"Arora","year":"2011","journal-title":"Journal of clinical and experimental hepatology"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Moy, Rappold, Williams, Kelly, Nicolodi, Maltzman, Goss. 2009. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. ASCO Annual Meeting Proceedings. p. 1043.","DOI":"10.1200\/jco.2009.27.15_suppl.1043"},{"issue":"2","key":"69","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-012-2369-x","article-title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","volume":"137","author":"Trudeau","year":"2013","journal-title":"Breast cancer research and treatment"},{"issue":"6","key":"70","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0284186X.2013.782103","article-title":"Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients","volume":"52","author":"Wu","year":"2013","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"3","key":"71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","article-title":"Imatinib mesylate as a cause of acute liver failure","volume":"81","author":"Gillett","year":"2006","journal-title":"American journal of hematology"},{"issue":"3","key":"72","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","article-title":"Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors","volume":"27","author":"Buyukberber","year":"2010","journal-title":"Medical oncology"},{"issue":"2","key":"73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","article-title":"Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials","volume":"29","author":"Tannock","year":"2011","journal-title":"Journal of clinical oncology"},{"issue":"4","key":"74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10408440590935620","article-title":"Role of metabolism in drug-induced idiosyncratic hepatotoxicity","volume":"35","author":"Thompson","year":"2005","journal-title":"Critical reviews in toxicology"},{"issue":"2","key":"75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Chan","year":"2015","journal-title":"Expert opinion on drug metabolism & toxicology"},{"issue":"2","key":"76","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Chalasani","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2007.06.001","article-title":"Mechanisms of drug-induced liver disease","volume":"11","author":"Kaplowitz","year":"2007","journal-title":"Clinics in liver disease"},{"issue":"1","key":"78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-199716010-00001","article-title":"Role of viral infections in the induction of adverse drug reactions","volume":"16","author":"Levy","year":"1997","journal-title":"Drug Saf"},{"issue":"5","key":"79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.13.24","article-title":"Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors","volume":"14","author":"Hunt","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"6","key":"80","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2010.09.028","article-title":"Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma","volume":"54","author":"Pandite","year":"2011","journal-title":"Journal of hepatology"},{"issue":"9","key":"81","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Pandite","year":"2010","journal-title":"British journal of cancer"},{"issue":"6","key":"82","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Rochon","year":"2008","journal-title":"Gastroenterology"},{"key":"83","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.drudis.2007.06.011","article-title":"Drug metabolism in the paediatric population and in the elderly","volume":"12","author":"Canning","year":"2007","journal-title":"Drug discovery today"},{"issue":"2","key":"84","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.lungcan.2015.08.004","article-title":"Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations","volume":"90","author":"Goto","year":"2015","journal-title":"Lung cancer"},{"issue":"5","key":"85","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cllc.2013.03.003","article-title":"Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity","volume":"14","author":"Tsuruta","year":"2013","journal-title":"Clinical lung cancer"},{"issue":"7","key":"86","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17425255.2016.1190831","article-title":"Hepatotoxicity of targeted therapy for cancer","volume":"12","author":"Chan","year":"2016","journal-title":"Expert opinion on drug metabolism & toxicology"},{"key":"87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12876-015-0380-5","article-title":"Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats","volume":"15","author":"Chen","year":"2015","journal-title":"BMC gastroenterology"},{"issue":"3","key":"88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3164\/jcbn.15-127","article-title":"Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib","volume":"58","author":"Sakaida","year":"2016","journal-title":"Journal of clinical biochemistry and nutrition"},{"issue":"1","key":"89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiological Reviews"},{"key":"90","first-page":"7","article-title":"Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis","author":"Weiskirchen","year":"2016","journal-title":"Frontiers in pharmacology"},{"issue":"2","key":"91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2012.02.011","article-title":"Drug targeting to the diseased liver","volume":"161","author":"Beljaars","year":"2012","journal-title":"J Control Release"},{"issue":"8","key":"92","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3748\/wjg.v12.i8.1303","article-title":"Arg-gly-asp-mannose-6-phosphate inhibits activation and proliferation of hepatic stellate cells in vitro","volume":"12","author":"Lu","year":"2006","journal-title":"World journal of gastroenterology"},{"issue":"1","key":"93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/17425247.2012.638625","article-title":"Specific delivery of kinase inhibitors in nonmalignant and malignant diseases","volume":"9","author":"Prakash","year":"2012","journal-title":"Expert opinion on drug delivery"},{"issue":"6","key":"94","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1039\/C4TB01611D","article-title":"Diagnostic imaging and therapeutic application of nanoparticles targeting the liver","volume":"3","author":"Roberts","year":"2015","journal-title":"Journal of Materials Chemistry B"},{"issue":"31","key":"95","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.3748\/wjg.v18.i31.4199","article-title":"Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells","volume":"18","author":"Wu","year":"2012","journal-title":"World journal of gastroenterology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:50:42Z","timestamp":1601056242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":95,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2016,10,11]]}},"alternative-id":["11767","27588502"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11767","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}